Table 2.
Outcomes by Empiric Therapy Received
| Overall | TZP | FQ | CR0 | SAM | MEM | FEP | |
|---|---|---|---|---|---|---|---|
| No. of patients (%) | 46 722 (100) | 25 070 (54.7) | 9339a (20.0) | 5006b (10.7) | 3492 (7.4) | 1308 (2.8) | 1331 (2.8) |
| LOT, median (IQR), d | 5 (3–8) | 4 (3–6) | 3 (1–5) | 2 (1–5) | 3 (1–4) | 5 (2–8) | 3 (1–5) |
| LOS, median (IQR), d | 4 (2–8) | 5 (3–8) | 5 (3–8) | 5 (3–9) | 4 (2–7) | 7 (4–12) | 7(4–12) |
| Hospital costs, median (IQR), $ | 12 345 (8447–20 399) | 12 377 (8591–19 748) | 12 823 (8829–20 836) | 13 995 (9336–22 470) | 11 723 (8409–18 509) | 18 256 (11 680–30 724) | 18 388 (11 047–31 101) |
| 30-d hospital re-admission, % | 9.9 | 9.7 | 9.4 | 9.9 | 8.9 | 12.8 | 12.2 |
| Hospital discharge location, % | |||||||
| Home | 88.9 | 89.5 | 87.1 | 85.0 | 91.7 | 78.0 | 76.5 |
| Hospital | 9.5 | 8.9 | 11.3 | 12.9 | 6.9 | 18.5 | 19.6 |
| Death | 0.9 | 0.9 | 0.9 | 1.1 | 0.8 | 2.1 | 2.4 |
| Hospice | 0.6 | 0.6 | 0.7 | 1.0 | 0.5 | 1.38 | 1.4 |
Abbreviations: CR0, ceftriaxone; FEP, cefepime; FQ, fluoroquinolones; IQR, interquartile range; LOS, hospital length of stay; LOT, length of therapy; MEM, meropenem; SAM, ampillin/sulbactam; TZP, piperacillin/tazobactam.
a8066 also received metronidazole.
b3959 also received metronidazole.